Hormone boost plus chemo aims to shrink hard-to-treat prostate cancer
NCT ID NCT03522064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a high dose of testosterone combined with the chemotherapy drug carboplatin can help men with a specific type of advanced prostate cancer that has stopped responding to standard hormone therapy. About 30 men with a genetic defect called homologous recombination deficiency will receive the treatment. The goal is to see if this approach can lower PSA levels and slow cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kinghorn Cancer Centre, St. Vincent's Hospital
RECRUITINGSydney, New South Wales, 2010, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can a new drug combo tame resistant prostate cancer?